Pancreatic Cancer Cells Starved by Compound Found in Vine

Researchers from the Institute of Organic Chemistry at the Julius Maximilian University of Würzburgin Germany and the Institute of Natural Medicine of the University of Toyama in Japan have discovered a potential new treatment for pancreatic cancer: a compound called ancistrolikokine E3, which is derived from twigs of the vine Ancistrocladus likoko . Pancreatic cancer is one of the leading causes of cancer deaths, with less than 10% of patients surviving beyond five years. Pancreatic cancer cell...
Continue reading

Adolescent Weight May Affect Adult Pancreatic Cancer Risk

​ A new study has found a link between obesity during adolescence and increased risk of pancreatic cancer during adulthood. Zohar Levi, MD, of Rabin Medical Center and Tel Aviv University, and colleagues examined Israeli data from 1,087,358 men and 707,212 women who underwent a mandatory physical examination between the ages of 16 and 19 during the years 1967 to 2002. The researchers then used the Israeli National Cancer Registry to identify which of these individuals developed pancreatic c...
Continue reading

ATRX Linked to Pancreatic Cancer Risk in Women

Results of a study conducted by Lawson Health Research Institute and Western University's Schulich School of Medicine and Dentistry show that mutation of a gene called ATRX is linked to increased risk of pancreatitis and pancreatic cancer in women. Conversely, in men, the mutation is associated with a lowered risk of pancreatic cancer. This discovery marks the first known sex-specific risk factor associated with the disease. The research team evaluated the effects of ATRX mutations in preclinica...
Continue reading

New Compound Bypasses Barrier to Pancreatic Cancer Treatment

A newly discovered compound called CEND-1 (iRGD) has recently entered a phase 1, open-label, multi-center study for the treatment of metastatic pancreatic cancer. CEND-1 was discovered at the Sanford Burnham Prebys Medical Discovery Institute (SBP) by Erkki Ruoslahti, MD, PhD. Currently, CEND-1 is licensed exclusively to DrugCendR Inc. Because pancreatic cancer has a 5-year survival rate of only 8.5%, there is a tremendous need for new and effective therapies. Like other solid tumors, pancreatic...
Continue reading

Diabetes Found to Increase Risk of Pancreatic Cancer in African Americans and Latinos

Type 2 diabetes, or adult-onset diabetes mellitus, comes with a handful of associated risks such as high blood pressure, nerve damage, kidney disease, stroke, and glaucoma. Research conducted by the Keck School of Medicine has found that in African American and Latino populations, a diabetes diagnosis between ages 65 and 85 is also directly linked to an increased risk of developing pancreatic cancer within 3 years. Since pancreatic cancer symptoms don't present until the disease is advanced, sur...
Continue reading
© Copyright 2018 i3 Health. All rights reserved.